Abstract
Numerous long noncoding RNAs (lncRNAs) have been identified as powerful regulators of human diseases. The lncRNA FOXD3-AS1 is a novel lncRNA that was recently shown to exert imperative roles in the initialization and progression of several diseases. Emerging studies have shown aberrant expression of FOXD3-AS1 and close correlation with pathophysiological traits of numerous diseases, particularly cancers. More importantly, FOXD3-AS1 was also found to ubiquitously impact a range of biological functions. This study aims to summarize the expression, associated clinicopathological features, major functions and molecular mechanisms of FOXD3-AS1 in human diseases and to explore its possible clinical applications.
Highlights
Frontiers in OncologyReceived: 04 January 2022 Accepted: 01 February 2022 Published: 25 February 2022
Based on the in-depth advance of high-throughput sequencing technologies, an emerging number of long non-coding RNAs has been identified over recent decades [1–5]
Previous evidence has indicated that FOXD3-AS1 is upregulated in Colon adenocarcinoma (COAD) tissues as well as in HCT116 and SW1116 cells, while its expression correlates with key clinical features, including: tumor node metastasis (TNM) stage, poor tumor differentiation, lymph node metastasis, overall survival and progression-free survival [36]
Summary
Received: 04 January 2022 Accepted: 01 February 2022 Published: 25 February 2022. Numerous long noncoding RNAs (lncRNAs) have been identified as powerful regulators of human diseases. The lncRNA FOXD3-AS1 is a novel lncRNA that was recently shown to exert imperative roles in the initialization and progression of several diseases. Emerging studies have shown aberrant expression of FOXD3-AS1 and close correlation with pathophysiological traits of numerous diseases, cancers. FOXD3-AS1 was found to ubiquitously impact a range of biological functions. This study aims to summarize the expression, associated clinicopathological features, major functions and molecular mechanisms of FOXD3-AS1 in human diseases and to explore its possible clinical applications
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call